Initial evaluation of human monoclonal anti-lipid A antibody (HA-1A) in patients with sepsis syndrome

Abstract

HA-1A, a human monoclonal immunoglobulin M antibody that binds specifically to the lipid A domain of endotoxin, was administered to sepatic patients to evaluate the safety, pharmacokinetics, and immunogenicity of the antibody. Thirty-four paitents received a single infusion of either 25 mg, 100 mg, or 250 mg, and were followed clinically for 14 to 21 days after treatment. HA-1A serum levels were measured before infusion and frequently after infusion with a radiometric assay. A one-compartment pharmacokinetic model was fit to the measured serum levels, and accurately described the changes in HA-1A level over time in each dose group (r2 = .99). The mean .+-. SEM apparent volume of distribution of HA-1A was 48.5 .+-. I 4.5 ml/kg, and the mean serum clearance was 2.8 .+-. 0.4 ml/kg .cntdot. h. The mean serum half-life of HA-1A was 15.9 .+-. 1.5 h. The mean serum level one hour after a 100-mg dose was 33.2 .+-. 2.4 .mu.g/ml, and the mean concentration 24 h later was 9.1 .+-. 1.6 .mu.g/ml. The dose administered and presence of Gram-negative bacterial infection did not significantly influence the volume of distribution or serum clearance. No adverse reactions to HA-1A were observed, and no antibodies against HA-1A were detected in any patient. These data indicate that the pharmacokinetics of HA-1A are well described by a one-compartment pharmacokinetic model, and that HA-1A is safe and nonimmunogenic in patients with sepsis.